FDA Grants Full Approval To Lilly's Inluriyo Plus Verzenio For ESR1-Mutated Breast Cancer

INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) announced that the U.S. Food and Drug Administration has granted full approval to Inluriyo (imlunestrant), an oral estrogen receptor (ER) antag...